Hosts discuss the latest data in psoriasis and the case for treating scalp, nail, and genital psoriasis as systemic-eligible disease.
ABCs in Dermatology
New AD biologic data highlight early systemic treatment, durable itch control, and improved pediatric growth—shifting goals beyond skin clearance.
Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.
Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.
Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.
Experts unpack biologics, molecular know-how, and patient trust—plus key previews for the upcoming AAD Annual Meeting.
Advertisement
Advertisement
Trending on HCPLive
1
Allergists Debate Newer Nonsteroidal Topicals for Atopic Dermatitis
2
Combination Therapy, Adherence, and Access: A PAH Expert Roundtable
3
CaRi-Heart Receives FDA De Novo Authorization for Coronary Inflammation
4
GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD
5